HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Dvorchik, B. Articles by Damphousse, D. Search for Related Content PubMed PubMed Citation Articles by Dvorchik, B. Articles by Damphousse, D. Social Bookmarking                   What's this?

Single-Dose Pharmacokinetics of Daptomycin in Young and Geriatric Volunteers

From Cubist Pharmaceuticals, Inc., Lexington, Massachusetts. Dr. Dvorchik's current affiliation is Barry Dvorchik and Associates, Inc., Tampa, Florida.

Daptomycin is a novel lipoprotein antibiotic that was recently approved for the treatment of complicated skin and skin structure infections caused by aerobic gram-positive bacteria. The pharmacokinetics of daptomycin was evaluated after a single 0.5-hour intravenous infusion of 4 mg/kg to groups of young adult (18-30 years) and geriatric ( 75 years) volunteers. Daptomycin was safe and well tolerated. No adverse events related to the infusion were reported. With increased age, there were increases in the area under the plasma concentration-time curve extrapolated to infinity (AUC) and the terminal elimination half-life. Systemic (CL) and renal clearance (CL_R) both decreased with increasing age. The observed changes seen in CL between the two cohorts were most likely a result of changes in renal function, as estimated by creatinine clearance. No statistically significant differences were observed between the two groups in the maximum plasma concentration (C_max) and volume of distribution at steady state (Vd_ss). The confidence intervals for the arithmetic mean ratios of the fraction of the dose excreted in the urine as daptomycin (%Fe) (geriatric subjects over younger subjects) were 60% to 101%, indicating that %Fe_dose was lower in geriatric subjects. These results demonstrate that changes in the pharmacokinetics of daptomycin in the elderly are attributable to changes in renal function, whereas age per se is not a significant factor.

Key Words: Daptomycin • pharmacokinetics • complicated skin and skin structure infections • antibiotic therapy • elderly vs. young volunteers

Address for reprints: Barry Dvorchik, PhD, FCP, Barry Dvorchik and Associates, Inc., 5809 Piney Lane Drive, Suite 105, Tampa, FL 33625.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Chakraborty, S. Roy, J. Loeffler, and R. L. Chaves Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection J. Antimicrob. Chemother., July 1, 2009; 64(1): 151 - 158. [Abstract] [Full Text] [PDF]

				J. S. Bubalo, M. Y. Munar, G. Cherala, B. Hayes-Lattin, and R. Maziarz Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever Antimicrob. Agents Chemother., February 1, 2009; 53(2): 428 - 434. [Abstract] [Full Text] [PDF]

				K. L. LaPlante, S. N. Leonard, D. R. Andes, W. A. Craig, and M. J. Rybak Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2156 - 2162. [Abstract] [Full Text] [PDF]

				M. P. Pai, J. P. Norenberg, T. Anderson, D. W. Goade, K. A. Rodvold, R. A. Telepak, and R.-C. Mercier Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2741 - 2747. [Abstract] [Full Text] [PDF]

				V. Huang and M. J. Rybak Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function J. Antimicrob. Chemother., January 1, 2006; 57(1): 116 - 121. [Abstract] [Full Text] [PDF]

				C. A. Schriever, C. Fernandez, K. A. Rodvold, and L. H. Danziger Daptomycin: A novel cyclic lipopeptide antimicrobial Am. J. Health Syst. Pharm., June 1, 2005; 62(11): 1145 - 1158. [Abstract] [Full Text] [PDF]

				B. H. Dvorchik and D. Damphousse The Pharmacokinetics of Daptomycin in Moderately Obese, Morbidly Obese, and Matched Nonobese Subjects J. Clin. Pharmacol., January 1, 2005; 45(1): 48 - 56. [Abstract] [Full Text] [PDF]